Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
21 results
  • Leukemia

14-035          Phase I

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation (View details on clinicaltrial.gov)

  • Leukemia

18-576          Phase II

A First-in-Human Phase 1/2a Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of FF-10101-01 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (View details on clinicaltrial.gov)

  • Leukemia

18-170          Phase I

A Phase 1 Study of ABL001 in combination with dasatinib and prednisone in patients with BCR-ABL positive (BCR-ABL+) B-cell acute lymphoblastic leukemia (B-ALL) and chronic myeloid leukemia (CML) (View details on clinicaltrial.gov)

  • Leukemia, Myelodysplastic Syndromes

19-358          Phase I

A Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (View details on clinicaltrial.gov)

  • Leukemia

20-205          Phase I

A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64619178, an Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) in Subjects with Advanced Cancers (View details on clinicaltrial.gov)

  • Leukemia

17-558          Phase I

A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects with Relapsed or Refractory Haematologic Malignancies (View details on clinicaltrial.gov)

  • Myelodysplastic Syndromes, Leukemia

14-191          Phase I

A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis) (View details on clinicaltrial.gov)

  • Leukemia

18-457          Phase II

A Phase 1b/2a open-label, multi-center study to assess the safety, efficacy and pharmacokinetics of intrapatient dose-adjusted brequinar and inhibition of dihydroorotate dehydrogenase (DHODH) in adult subjects with acute myelogenous leukemia (AML) (View details on clinicaltrial.gov)

Showing 1 - 10 of 21 results